CA2375049A1 - Compositions et methodes pour traiter, diagnostiquer et surveiller l'evolution du cancer du sein - Google Patents

Compositions et methodes pour traiter, diagnostiquer et surveiller l'evolution du cancer du sein Download PDF

Info

Publication number
CA2375049A1
CA2375049A1 CA002375049A CA2375049A CA2375049A1 CA 2375049 A1 CA2375049 A1 CA 2375049A1 CA 002375049 A CA002375049 A CA 002375049A CA 2375049 A CA2375049 A CA 2375049A CA 2375049 A1 CA2375049 A1 CA 2375049A1
Authority
CA
Canada
Prior art keywords
patient
mammaglobin
antibody
cells
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002375049A
Other languages
English (en)
Inventor
Gary Richard Fanger
Ronald C. Hendrickson
Raymond L. Houghton
Steven G. Reed
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2375049A1 publication Critical patent/CA2375049A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4721—Lipocortins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

L'invention concerne des compositions et des méthodes permettant de traiter, de diagnostiquer et de surveiller l'évolution du cancer du sein. Les compositions de cette invention peuvent renfermer un ou plusieurs épitopes de mammaglobine, ou des anticorps ou des lymphocytes T de ceux-ci, et peuvent par exemple être utilisées pour prévenir et traiter le cancer du sein. Cette invention concerne également des méthodes de diagnostic s'appuyant sur la détection de la présence de ces épitopes de mammaglobine, ou des anticorps ou des lymphocytes T de ceux-ci, dans un échantillon. Cette invention concerne enfin des méthodes permettant de détecter l'ARN codant pour la mammaglobine dans le sang d'un patient ou dans des fractions de ce sang, ces méthodes pouvant être utilisées pour détecter et/ou surveiller la progression du cancer du sein.
CA002375049A 1999-05-28 2000-05-26 Compositions et methodes pour traiter, diagnostiquer et surveiller l'evolution du cancer du sein Abandoned CA2375049A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13652899P 1999-05-28 1999-05-28
US60/136,528 1999-05-28
US13704899P 1999-06-01 1999-06-01
US60/137,048 1999-06-01
PCT/US2000/014845 WO2000073338A1 (fr) 1999-05-28 2000-05-26 Compositions et méthodes pour traiter, diagnostiquer et surveiller l'évolution du cancer du sein

Publications (1)

Publication Number Publication Date
CA2375049A1 true CA2375049A1 (fr) 2000-12-07

Family

ID=26834387

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375049A Abandoned CA2375049A1 (fr) 1999-05-28 2000-05-26 Compositions et methodes pour traiter, diagnostiquer et surveiller l'evolution du cancer du sein

Country Status (5)

Country Link
EP (1) EP1185557A1 (fr)
JP (1) JP2003502028A (fr)
AU (1) AU5449600A (fr)
CA (1) CA2375049A1 (fr)
WO (1) WO2000073338A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044859A1 (en) * 1996-08-19 2003-03-06 Henslee Jerry G. Reagents and methods useful for detecting diseases of the breast
WO2002053017A2 (fr) * 2001-01-08 2002-07-11 Corixa Corporation Compositions et methodes destinees a la therapie, au diagnostic et la surveillance du cancer du sein
CN108864272B (zh) * 2018-07-03 2021-04-27 中国人民解放军军事科学院军事医学研究院 一种乳腺珠蛋白a抗原表位及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922836A (en) * 1995-05-31 1999-07-13 Washington University Mammaglobin antigens
US5668267A (en) * 1995-05-31 1997-09-16 Washington University Polynucleotides encoding mammaglobin, a mammary-specific breast cancer protein
AU728777B2 (en) * 1996-01-11 2001-01-18 Corixa Corporation Compositions and methods for the treatment and diagnosis of breast cancer
WO1998007753A1 (fr) * 1996-08-19 1998-02-26 Abbott Laboratories Mammoglobines, anticorps contre celles-ci et leur utilisation pour la detection des maladies du sein
JP2001520015A (ja) * 1997-10-16 2001-10-30 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト・マンモグロビンホモログ

Also Published As

Publication number Publication date
WO2000073338A9 (fr) 2002-01-24
WO2000073338A8 (fr) 2001-05-25
EP1185557A1 (fr) 2002-03-13
JP2003502028A (ja) 2003-01-21
WO2000073338A1 (fr) 2000-12-07
AU5449600A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
EP1169347B1 (fr) Composes et procedes de therapie et de diagnostic du cancer du poumon
EP1183348B1 (fr) Compositions pour le traitement et le diagnostic du cancer du sein et leurs procedes d'utilisation
WO2002013847A2 (fr) Methodes diagnostiques et therapeutiques des tumeurs malignes d'origine hematologiques et virales
EP1141290A2 (fr) Compositions et procedes destines a la therapie et au diagnostic du cancer de l'ovaire
EP1097208A2 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
CA2383615A1 (fr) Procedes de diagnostic et de therapie de malignites hematologiques ou associees aux virus
US20010055596A1 (en) Compositions and methods for therapy and diagnosis of colon cancer
US20020150588A1 (en) SPAS-1 cancer antigen
WO2000052165A2 (fr) Compositions et methodes de therapie et de diagnostic du cancer du sein
WO2001051513A2 (fr) Sequences associees a une tumeur ovarienne
US20020058292A1 (en) Ovarian tumor antigen and methods of use therefor
NZ567750A (en) Compositions and uses for cancer therapy
US6933363B1 (en) Compositions and methods for therapy and diagnosis of lung cancer
US20020064815A1 (en) Ovarian tumor antigen and methods of use therefor
US20020155468A1 (en) Ovarian tumor antigen and methods of use therefor
CA2375049A1 (fr) Compositions et methodes pour traiter, diagnostiquer et surveiller l'evolution du cancer du sein
US20030045468A1 (en) Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
US20020082216A1 (en) Compositions and methods for the therapy, diagnosis and monitoring of breast cancer
WO2002053017A2 (fr) Compositions et methodes destinees a la therapie, au diagnostic et la surveillance du cancer du sein
AU2007216683B2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
AU2003271300B2 (en) Compositions and methods for therapy and diagnosis of ovarian cancer
WO2001027276A2 (fr) Sequences de tumeur du sein et leurs procedes d'utilisation

Legal Events

Date Code Title Description
FZDE Discontinued